Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476368 | 0.91 | NAMPT (0.54) | NAMPTALDH1A1KMT2AMAPT | |
| SCHEMBL3477801 | 0.91 | ALDH1A1 (0.43) | NAMPTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL3476271 | 0.90 | NAMPT (0.57) | NAMPTALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3476335 | 0.90 | NAMPT (0.45) | NAMPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3477794 | 0.89 | NAMPT (0.57) | NAMPTCNR1CNR2ALDH1A1MEN1 | |
| SCHEMBL3476809 | 0.89 | KDM4E (0.41) | NAMPTCNR1CNR2ALDH1A1MEN1 | |
| SCHEMBL3476752 | 0.88 | LMNA (0.43) | NAMPTCNR1ALDH1A1MEN1KMT2A | |
| SCHEMBL3476812 | 0.87 | NPC1 (0.50) | NAMPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL3477114 | 0.86 | MAPT (0.51) | NAMPTCNR1ALDH1A1CA12CA9 | |
| SCHEMBL3477440 | 0.86 | LMNA (0.43) | CNR1CNR2ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898927-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007002481-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, RTF1, POLR1E | NAMPT 58/4885CNR1 4488/4885CNR2 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.